Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 9

See more details

Referenced in 23 patents
21 readers on Mendeley
  • Article usage
  • Citations to this article (56)

Advertisement

Research Article Free access | 10.1172/JCI117259

Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

P Lollar, E T Parker, J E Curtis, S L Helgerson, L W Hoyer, M E Scott, and D Scandella

Department of Medicine, Emory University, Atlanta, Georgia 30322.

Find articles by Lollar, P. in: JCI | PubMed | Google Scholar

Department of Medicine, Emory University, Atlanta, Georgia 30322.

Find articles by Parker, E. in: JCI | PubMed | Google Scholar

Department of Medicine, Emory University, Atlanta, Georgia 30322.

Find articles by Curtis, J. in: JCI | PubMed | Google Scholar

Department of Medicine, Emory University, Atlanta, Georgia 30322.

Find articles by Helgerson, S. in: JCI | PubMed | Google Scholar

Department of Medicine, Emory University, Atlanta, Georgia 30322.

Find articles by Hoyer, L. in: JCI | PubMed | Google Scholar

Department of Medicine, Emory University, Atlanta, Georgia 30322.

Find articles by Scott, M. in: JCI | PubMed | Google Scholar

Department of Medicine, Emory University, Atlanta, Georgia 30322.

Find articles by Scandella, D. in: JCI | PubMed | Google Scholar

Published June 1, 1994 - More info

Published in Volume 93, Issue 6 on June 1, 1994
J Clin Invest. 1994;93(6):2497–2504. https://doi.org/10.1172/JCI117259.
© 1994 The American Society for Clinical Investigation
Published June 1, 1994 - Version history
View PDF
Abstract

Human inhibitory alloantibodies and autoantibodies to Factor VIII (FVIII) are usually directed toward the A2 and/or C2 domains of the FVIII molecule. Anti-C2 antibodies block the binding of FVIII to phospholipid, but the mechanism of action of anti-A2 antibodies is not known. We investigated the properties of a patient autoantibody, RC, and a monoclonal antibody, 413, that bind to the region which contains the epitopes of all anti-A2 alloantibodies or autoantibodies studied to date. mAb 413 and RC were noncompetitive inhibitors of a model intrinsic Factor X activation complex (intrinsic FXase) consisting of Factor IXa, activated FVIII (FVIIIa), and synthetic phospholipid vesicles, since they decreased the Vmax of intrinsic FXase by > 95% at saturating concentrations without altering the Km. This indicates that RC and mAb 413 either block the binding of FVIIIa to FIXa or phospholipid or interfere with the catalytic function of fully assembled intrinsic FXase, but they do not inhibit the binding of the substrate Factor X. mAb 413 did not inhibit the increase in fluorescence anisotropy that results from the binding of Factor VIIIa to fluorescein-5-maleimidyl-D-phenylalanyl-prolyl-arginyl-FIXa (Fl-M-FPR-FIXa) on phospholipid vesicles in the absence of Factor X, indicating it does not inhibit assembly of intrinsic FXase. Addition of Factor X to Fl-M-FPR-FIXa, FVIIIa, and phospholipid vesicles produced a further increase in fluorescence anisotropy and a decrease in fluorescence intensity. This effect was blocked completely by mAb 413. We conclude that anti-A2 antibodies inhibit FVIIIa function by blocking the conversion of intrinsic FXase/FX complex to the transition state, rather than by interfering with formation of the ground state Michaelis complex.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2497
page 2497
icon of scanned page 2498
page 2498
icon of scanned page 2499
page 2499
icon of scanned page 2500
page 2500
icon of scanned page 2501
page 2501
icon of scanned page 2502
page 2502
icon of scanned page 2503
page 2503
icon of scanned page 2504
page 2504
Version history
  • Version 1 (June 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 9
  • Article usage
  • Citations to this article (56)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 23 patents
21 readers on Mendeley
See more details